Articles related to PATIENT EDUCATION

Consumer-facing guidance from Verywell Mind highlights how depression in adults over 60 frequently manifests as somatic complaints, cognitive changes, and social withdrawal rather than overt mood symptoms.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

Three recent studies examined associations between vitamin D status and outcomes across type 2 diabetes risk, Alzheimer’s biomarkers, and inflammatory bowel disease in exploratory cohorts.

A SARS-CoV-2 variant designated BA.3.2, or “Cicada,” has been added to the WHO variants under monitoring list, with wastewater detection across at least 25 US states and 132 locations.

Eleven commonly prescribed medication classes have been associated with new or worsening depression symptoms, with risk varying by dose, duration, and patient population.

Stroke incidence is rising in women under 45, with attention turning to non-traditional risk factors including handheld percussive devices, sexual strangulation, migraine with aura, peripartum vascular changes, and early menopause.